Ambys Overview

  • Founded
  • 2016
  • Status
  • Private
  • Latest Deal Type
  • Corporate
  • Latest Deal Amount
  • $80M
Latest Deal Amount
  • Investors
  • 2

Ambys General Information


Developer of regenerative medical therapies intended to cure serious liver diseases. The company's medical therapies help in restoring liver function, preventing the progression of liver disease and treating the devastating complications of liver failure, enabling patients suffering from chronic liver diseases to get relief from disease through different medical therapies, including cell therapy for hepatocyte transplantation, gene therapy for liver regeneration and drug therapy to replace lost protein function.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Primary Office
  • 131 Oyster Point Boulevard
  • Suite 200
  • South San Francisco, CA 94080
  • United States
+1 (650) 000-0000

Ambys Timeline

Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Ambys Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Corporate 08-Aug-2018 $80M 00000 Completed Product Development
1. Early Stage VC (Series A) 08-Aug-2018 0000 0000 Completed Product Development
To view Ambys’s complete valuation and funding history, request access »

Ambys Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A 00,000,000 00.000000 00 00 00 00 000
To view Ambys’s complete cap table history, request access »

Ambys Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of regenerative medical therapies intended to cure serious liver diseases. The company's medical therapies hel
Drug Discovery
South San Francisco, CA
000000000000 00000

0000 000

tate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proide
0000 000000000
Cambridge, MA
00 As of 0000
0000 0000-00-00
00000000000 00000

00000 00

xercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in repreh
0000 000000000
New York, NY
00 As of 0000
000000000000 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ambys Competitors (29)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aura Biosciences Venture Capital-Backed Cambridge, MA 00 00000 00000000000 00000
00000 000000000000 Formerly VC-backed New York, NY 00 000.00 000000000000 000.00
0000000000 0000000 Venture Capital-Backed Mont-Saint-Guibert, Belgium 00 00000 00000000000 00000
0000 0000000000000 Venture Capital-Backed South San Francisco, CA 0 0000 00000000000 0000
000000000 Venture Capital-Backed Gaithersburg, MD 00 000.00 00000000000 000.00
You’re viewing 5 of 29 competitors. Get the full list »

Ambys Executive Team (9)

Name Title Board Seat Contact Info
Jeff Jonker JD Chief Executive Officer & President
Michael Holmes Ph.D Chief Scientific Officer
Amanda Valentino Chief People Officer
Holger Willenbring Ph.D Co-Founder
Juan Carlos Belmonte Ph.D Co-Founder
You’re viewing 5 of 9 executive team members. Get the full list »

Ambys Board Members (4)

Name Representing Role Since
Asit Parikh Ph.D Takeda Pharmaceutical Company Board Member 000 0000
Charles Homcy MD Third Rock Ventures Board Member 000 0000
Michael Martin Ph.D Self Board Observer 000 0000
To view Ambys’s complete board members history, request access »

Ambys Investors (2)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Takeda Pharmaceutical Company Corporation Minority 000 0000 000000 0
Third Rock Ventures Venture Capital Minority 000 0000 000000 0
To view Ambys’s complete investors history, request access »